Cancer Risk Prediction Models:
A Workshop on Development, Evaluation, and Application
A great deal of research has recently been published or is currently
underway to develop risk prediction models to accurately estimate the
absolute risk of cancer in average-risk individuals, as well as develop
models to estimate genetic susceptibility carrier status in high-risk
The Cancer Risk Prediction Workshop has been planned to bring together experts in the emerging field of cancer risk prediction to:
Identify cancer risk prediction model applications and their usefulness in planning intervention trials, estimating the population burden of disease, creating benefit/risk indices and clinical decision making processes, and designing prevention strategies.
Discuss the strengths and limitations of cancer risk prediction models in current use and under development.
Discuss methodological issues relevant to the evaluation, validation, and discrimination of cancer risk prediction models.
Identify ways to improve current and future cancer risk prediction models, incorporating new clinical, environmental, and genetic data.
Identify research needs and population data resources for future cancer risk prediction modeling and validation and disseminate this information to the scientific community.
Co-Chairs of the Cancer Risk Prediction Planning Committee
Andrew Freedman, Ph.D., National Cancer Institute
Ruth Pfeiffer, Ph.D., National Cancer Institute
Members of the Cancer Risk Prediction Planning Committee
Daniela Seminara, Ph.D., M.P.H., National Cancer Institute
Rachel Ballard-Barbash, M.D., M.P.H., National Cancer Institute
Mitchell Gail, M.D., Ph.D., National Cancer Institute
Graham Colditz, M.D., Dr.P.H., Brigham and Women's Hospital, Harvard Medical School
Patricia Hartge, Sc.D., National Cancer Institute
Co-sponsored by NCI's Office of Women's Health